RG7314 is a selective small molecule antagonist of the vasopressin V1A receptor which is under development by Roche for the treatment of autism. As of August 2014, it is in phase II clinical trials for this indication.
- "Roche - Pipeline". 2014. Retrieved 2014-08-01.
- A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders, at ClinicalTrials.gov; retrieved September 2, 2014
Lua error in package.lua at line 80: module 'Module:Buffer' not found.